Dynamic observation of bone marrow suppression and chromosomal aberrations in patients with acute colchicine poisoning

• 作者: Yan-qing Liu Xiao-xia Lu Kai-xun Hu Xiao-bo Peng Yun Jiang Li-mei Han Zhi-qiang Ma Ming-fei Peng Kun Wan Xi-gang Zhang Ze-wu Qiu
• 来源期刊: 世界急诊医学杂志（英文版）
• 年，卷（期）: 2022,（2）
• 所属期刊栏目: Research Letters
• 页码范围: 130-134
• 页数: 5页
• 语种: 中文
• DOI: 10.5847/wjem.j.1920-8642.2022.030

摘要

Colchicine is a neutral lipophilic tricyclic alkaloid toxic to human cells containing tubulin,[1-2] and primarily stops the proliferation of active cells in the mitotic metaphase, such as intestinal mucosal cells and hematopoietic cells. It is widely used in treating gout and familial Mediterranean fever, while it is also used in establishing animal and plant experimental model.[3] In the recent study, treatment of patients affected by coronavirus disease 2019 (COVID-19) with colchicine may prove a viable path.[4] The course of colchicine poisoning can be divided into three stages,[5] and most of the patients died in the second stage (2–7 d, the multiple organ injury stage). The cause of death was heart failure [6] and bone marrow hematopoietic failure in the terminal phase.[7] Hematopoiesis is a classic sign of colchicine poisoning. Many cases of colchicine poisoning have been comprehensively reported, and the target organs included heart, digestive tract, muscle, lung, kidney, hematopoietic system, etc.[8-11] This study aimed to investigate the injury of bone marrow hematopoietic system after colchicine poisoning and evaluate the therapeutic effect of bone marrow hematopoietic stimulation drugs.